Anca D. Askanase, MD, MPH, shares potential highlights for the upcoming ACR Convergence 2024 and how excitement is building in the area of lupus therapeutics development, including two phase 3 trials announcing positive results — one for obinutuzumab in lupus nephritis and another for dapirolizumab in systemic lupus erythematosus. Although the full results won't be presented at the upcoming ACR conference, a post hoc analysis of the obinutuzumab phase 2 data will be shared.
Attendees can also look forward to the unveiling of new lupus nephritis guidelines, reflecting over a year of effort by experts. Additionally, there will be sessions on the potential of cell therapy, including CAR T-cell therapy, to offer new treatment avenues. Overall, this ACR conference signifies a promising shift toward better therapeutic outcomes, with discussions around achieving low disease activity, remission, and even the possibility of a drug-free cure for lupus.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ACR 2024: Promising Advances in Lupus Nephritis and SLE Therapeutics - Medscape - Nov 07, 2024.
Comments